The Goodwin Life Sciences team advised Esperion Therapeutics, Inc. (Nasdaq: ESPR) (“Esperion”) on its underwritten public offering of 30,000,000 shares of its common stock at a public offering price of $2.50 per share. All of the shares of common stock in the offering were sold by Esperion. The gross proceeds to Esperion from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $75 million.
Esperion is a commercial-stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. Esperion developed and is commercializing the only FDA approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline.
The Goodwin team was led by Mitchell Bloom, Adam Johnson, Karin Yoo, Andrea Akinbola and Angela Kim, and included Michael Shuster, Duncan Greenhalgh and Gina Jane Kim; Julie Tibbets; and Ettore Santucci.
For more information, please read the press release.